FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2293854741> ?p ?o ?g. }

• W2293854741 endingPage "e0147743" @default.
• W2293854741 startingPage "e0147743" @default.
• W2293854741 abstract "Background This was the first microbicide trial conducted in Africa to evaluate an antiretroviral-containing vaginal ring as an HIV prevention technology for women. Objectives The trial assessed and compared the safety, acceptability and adherence to product use of a 4-weekly administered vaginal ring containing the antiretroviral microbicide, dapivirine, with a matching placebo ring among women from four countries in sub-Saharan Africa. Methods 280 Healthy, sexually active, HIV-negative women, aged 18 to 40 years were enrolled with 140 women randomised to a dapivirine vaginal ring (25 mg) and 140 women to a matching placebo ring, inserted 4-weekly and used over a 12-week period. Safety was evaluated by pelvic examination, colposcopy, clinical laboratory assessments, and adverse events. Blood samples for determination of plasma concentrations of dapivirine were collected at Weeks 0, 4 and 12. Residual dapivirine levels in returned rings from dapivirine ring users were determined post-trial. Participant acceptability and adherence to ring use were assessed by self-reports. Results No safety concerns or clinically relevant differences were observed between the dapivirine and placebo ring groups. Plasma dapivirine concentrations immediately prior to ring removal were similar after removal of the first and third ring, suggesting consistent ring use over the 12-week period. No clear relationship was observed between the residual amount of dapivirine in used rings and corresponding plasma concentrations. Self-reported adherence to daily use of the vaginal rings over the 12-week trial period was very high. At the end of the trial, 96% of participants reported that the ring was usually comfortable to wear, and 97% reported that they would be willing to use it in the future if proven effective. Conclusions The dapivirine vaginal ring has a favourable safety and acceptability profile. If proven safe and effective in large-scale trials, it will be an important component of combination HIV prevention approaches for women. Trial Registration ClinicalTrials.gov NCT01071174" @default.
• W2293854741 created "2016-06-24" @default.
• W2293854741 creator A5004352759 @default.
• W2293854741 creator A5008190070 @default.
• W2293854741 creator A5025213594 @default.
• W2293854741 creator A5039983859 @default.
• W2293854741 creator A5040320882 @default.
• W2293854741 creator A5046970568 @default.
• W2293854741 creator A5052037065 @default.
• W2293854741 creator A5058300507 @default.
• W2293854741 creator A5063099394 @default.
• W2293854741 creator A5066713628 @default.
• W2293854741 creator A5072522329 @default.
• W2293854741 creator A5078477980 @default.
• W2293854741 creator A5079982575 @default.
• W2293854741 date "2016-03-10" @default.
• W2293854741 modified "2023-10-18" @default.
• W2293854741 title "Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa" @default.
• W2293854741 cites W1519189873 @default.
• W2293854741 cites W1980136429 @default.
• W2293854741 cites W2015768353 @default.
• W2293854741 cites W2025396127 @default.
• W2293854741 cites W2044369525 @default.
• W2293854741 cites W2062612064 @default.
• W2293854741 cites W2080796474 @default.
• W2293854741 cites W2088038800 @default.
• W2293854741 cites W2146634980 @default.
• W2293854741 cites W2150620920 @default.
• W2293854741 cites W2169093937 @default.
• W2293854741 cites W2172050987 @default.
• W2293854741 doi "https://doi.org/10.1371/journal.pone.0147743" @default.
• W2293854741 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4786336" @default.
• W2293854741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26963505" @default.
• W2293854741 hasPublicationYear "2016" @default.
• W2293854741 type Work @default.
• W2293854741 sameAs 2293854741 @default.
• W2293854741 citedByCount "87" @default.
• W2293854741 countsByYear W22938547412016 @default.
• W2293854741 countsByYear W22938547412017 @default.
• W2293854741 countsByYear W22938547412018 @default.
• W2293854741 countsByYear W22938547412019 @default.
• W2293854741 countsByYear W22938547412020 @default.
• W2293854741 countsByYear W22938547412021 @default.
• W2293854741 countsByYear W22938547412022 @default.
• W2293854741 countsByYear W22938547412023 @default.
• W2293854741 crossrefType "journal-article" @default.
• W2293854741 hasAuthorship W2293854741A5004352759 @default.
• W2293854741 hasAuthorship W2293854741A5008190070 @default.
• W2293854741 hasAuthorship W2293854741A5025213594 @default.
• W2293854741 hasAuthorship W2293854741A5039983859 @default.
• W2293854741 hasAuthorship W2293854741A5040320882 @default.
• W2293854741 hasAuthorship W2293854741A5046970568 @default.
• W2293854741 hasAuthorship W2293854741A5052037065 @default.
• W2293854741 hasAuthorship W2293854741A5058300507 @default.
• W2293854741 hasAuthorship W2293854741A5063099394 @default.
• W2293854741 hasAuthorship W2293854741A5066713628 @default.
• W2293854741 hasAuthorship W2293854741A5072522329 @default.
• W2293854741 hasAuthorship W2293854741A5078477980 @default.
• W2293854741 hasAuthorship W2293854741A5079982575 @default.
• W2293854741 hasBestOaLocation W22938547411 @default.
• W2293854741 hasConcept C117214928 @default.
• W2293854741 hasConcept C126322002 @default.
• W2293854741 hasConcept C131872663 @default.
• W2293854741 hasConcept C142724271 @default.
• W2293854741 hasConcept C159047783 @default.
• W2293854741 hasConcept C197746943 @default.
• W2293854741 hasConcept C197934379 @default.
• W2293854741 hasConcept C204787440 @default.
• W2293854741 hasConcept C27081682 @default.
• W2293854741 hasConcept C2779076696 @default.
• W2293854741 hasConcept C2779755712 @default.
• W2293854741 hasConcept C2908647359 @default.
• W2293854741 hasConcept C29456083 @default.
• W2293854741 hasConcept C2986740045 @default.
• W2293854741 hasConcept C2986817661 @default.
• W2293854741 hasConcept C3013748606 @default.
• W2293854741 hasConcept C535046627 @default.
• W2293854741 hasConcept C71924100 @default.
• W2293854741 hasConcept C99454951 @default.
• W2293854741 hasConceptScore W2293854741C117214928 @default.
• W2293854741 hasConceptScore W2293854741C126322002 @default.
• W2293854741 hasConceptScore W2293854741C131872663 @default.
• W2293854741 hasConceptScore W2293854741C142724271 @default.
• W2293854741 hasConceptScore W2293854741C159047783 @default.
• W2293854741 hasConceptScore W2293854741C197746943 @default.
• W2293854741 hasConceptScore W2293854741C197934379 @default.
• W2293854741 hasConceptScore W2293854741C204787440 @default.
• W2293854741 hasConceptScore W2293854741C27081682 @default.
• W2293854741 hasConceptScore W2293854741C2779076696 @default.
• W2293854741 hasConceptScore W2293854741C2779755712 @default.
• W2293854741 hasConceptScore W2293854741C2908647359 @default.
• W2293854741 hasConceptScore W2293854741C29456083 @default.
• W2293854741 hasConceptScore W2293854741C2986740045 @default.
• W2293854741 hasConceptScore W2293854741C2986817661 @default.
• W2293854741 hasConceptScore W2293854741C3013748606 @default.
• W2293854741 hasConceptScore W2293854741C535046627 @default.
• W2293854741 hasConceptScore W2293854741C71924100 @default.
• W2293854741 hasConceptScore W2293854741C99454951 @default.

• next